Staging
Relationship to TNM Staging
Anatomic staging is not applicable to the leukemias.
Relationship to Summary Staging
All leukemias are considered disseminated at time of diagnosis.
Prognostic and Therapeutic Stagings
Stage | Description |
---|---|
Stage 0 | Lymphocytosis greater than 5,000 cell/mm and greater than 40% of cells in the bone marrow |
Stage 1 | Lymphocytosis with large lymph nodes |
Stage 2 | Lymphocytosis with enlargement of spleen and/or liver |
Stage 3 | Lymphocytosis and marrow replacement resulting in anemia |
Stage 4 | Lymphocytosis and low platelet due to marrow replacement |
International Workshop on CLL Clinical Staging
- Clinical stage A
- No anemia or thrombocytopenia, < 3 areas of lymphadenopathy
(Rai Stage 0, I, II)
- No anemia or thrombocytopenia, < 3 areas of lymphadenopathy
- Clinical stage B
- No anemia or thrombocytopenia, > or = 3 areas of lymphadenopathy (Rai Stage I - II)
- Clinical stage C
- Anemia and/or thrombocytopenia (Rai Stage III - IV)
There are no staging systems for other blood diseases. The acute leukemias and myelodysplastic syndromes are described and classified histologically by the French-American-British (FAB) classification.
An International Prognostic Scoring System has been developed for MDS, based on the bone marrow blast percentage, number of peripheral blood cytopenias, and cytogenetic subgroup, which stratifies cases into four risk groups. In addition, other prognostic classification systems for MDS include the FAB system (described above), the Bournemouth score, the Sanz score, and the Lille score.
Collaborative Stage Elements
For more details on Collaborative Stage, see the Intro to Collaborative Staging module.